Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease

2013 ◽  
Vol 13 (6) ◽  
pp. 695-705 ◽  
Author(s):  
Michael R Douglas
2015 ◽  
Vol 23 ◽  
pp. S79-S80
Author(s):  
Romina Aron Badin ◽  
Katie Binley ◽  
Nadja Van Camp ◽  
Caroline Jan ◽  
Jean Gourlay ◽  
...  

2021 ◽  
pp. 1-9
Author(s):  
Tomas Björklund ◽  
Marcus Davidsson

Recent technological and conceptual advances have resulted in a plethora of exciting novel engineered adeno associated viral (AAV) vector variants. They all have unique characteristics and abilities. This review summarizes the development and their potential in treating Parkinson’s disease (PD). Clinical trials in PD have shown over the last decade that AAV is a safe and suitable vector for gene therapy but that it also is a vehicle that can benefit significantly from improvement in specificity and potency. This review provides a concise collection of the state-of-the-art for synthetic capsids and their utility in PD. We also summarize what therapeutical strategies may become feasible with novel engineered vectors, including genome editing and neuronal rejuvenation.


2012 ◽  
Vol 18 ◽  
pp. S102
Author(s):  
J. Cancela González ◽  
M. Pastorino ◽  
L. Pastor-Sanz ◽  
A.P. Gonzalez Marcos ◽  
M.T. Arredondo Waldmeyer

2005 ◽  
Vol 32 (S 4) ◽  
Author(s):  
A.H Jacobs ◽  
R Hilker ◽  
L Burghaus ◽  
W.D Heiss

Sign in / Sign up

Export Citation Format

Share Document